{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:42:29Z","timestamp":1757619749376,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"STADA Arzneimittel AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03319-z","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T13:25:10Z","timestamp":1753449910000},"page":"4597-4610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of XSB-001 (Ranibizumab Biosimilar) Physicochemical and Biological Stability in Prepared Syringes for Intravitreal Injection"],"prefix":"10.1007","volume":"42","author":[{"given":"Robert","family":"Bj\u00f6rnestedt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Au\u0161rin\u0117","family":"Pai\u0161yt\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabricio","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"22","key":"3319_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480\u20137.","journal-title":"N Engl J Med"},{"issue":"6","key":"3319_CR2","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248\u201364.","journal-title":"Cell"},{"issue":"6 Suppl","key":"3319_CR3","first-page":"S81","volume":"29","author":"A Almony","year":"2023","unstructured":"Almony A. Treatment approaches for neovascular age-related macular degeneration and diabetic macular edema. Am J Manag Care. 2023;29(6 Suppl):S81\u20139.","journal-title":"Am J Manag Care"},{"key":"3319_CR4","unstructured":"EMA. Ximluci: EPAR - Product Information December 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ximluci-epar-product-information_en.pdf."},{"issue":"2","key":"3319_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/eye.2015.217","volume":"30","author":"V Chong","year":"2016","unstructured":"Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye. 2016;30(2):270\u201386.","journal-title":"Eye"},{"issue":"3","key":"3319_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682\u201392 (e2).","journal-title":"Ophthalmology"},{"issue":"10","key":"3319_CR7","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","volume":"119","author":"R Varma","year":"2012","unstructured":"Varma R, Bressler NM, Su\u00f1er I, Lee P, Dolan CM, Ward J, et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012;119(10):2108\u201318.","journal-title":"Ophthalmology"},{"issue":"12","key":"3319_CR8","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","volume":"124","author":"R Tadayoni","year":"2017","unstructured":"Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology. 2017;124(12):1778\u201387.","journal-title":"Ophthalmology"},{"issue":"2","key":"3319_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.oret.2017.05.016","volume":"2","author":"M Larsen","year":"2018","unstructured":"Larsen M, Waldstein SM, Priglinger S, Hykin P, Barnes E, Gekkieva M, et al. Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the CRYSTAL study. Ophthalmol Retina. 2018;2(2):134\u201342.","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"3319_CR10","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","volume":"33","author":"P Massin","year":"2010","unstructured":"Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study) A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399\u2013405.","journal-title":"Diabetes Care"},{"issue":"4","key":"3319_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615\u201325.","journal-title":"Ophthalmology"},{"issue":"6","key":"3319_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","volume":"100","author":"C Pr\u00fcnte","year":"2016","unstructured":"Pr\u00fcnte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studni\u010dka J, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100(6):787\u201395.","journal-title":"Br J Ophthalmol"},{"key":"3319_CR13","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1007\/s11606-019-05408-6","volume":"35","author":"EH Jung","year":"2020","unstructured":"Jung EH, Sarpatwari A, Kesselheim AS, Sinha MS. FDA and EMA biosimilar approvals. J Gen Intern Med. 2020;35:1908\u201310.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"3319_CR14","first-page":"225","volume":"1540","author":"HN Kang","year":"2024","unstructured":"Kang HN, Wadhwa M, Knezevic I, Burns C, Griffiths E. The importance of World Health Organization international reference standards in the product life cycle of biosimilars. Ann N Y Acad Sci. 2024;1540(1):225\u201334.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"3319_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.13.7.17","volume":"13","author":"M Lombardo","year":"2024","unstructured":"Lombardo M, Missiroli F, Cerri L, Sorge RP, Cesareo M, Ricci F. Real-world use of off-label MVASI in the treatment of patients with neovascular AMD and DME. Transl Vis Sci Technol. 2024;13(7):17.","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"3319_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/ceo.12489","volume":"43","author":"T Das","year":"2015","unstructured":"Das T, Volety S, Ahsan SM, Thakur AK, Sharma S, Padhi TR, et al. Safety, sterility and stability of direct-from-vial multiple dosing intravitreal injection of bevacizumab. Clin Experiment Ophthalmol. 2015;43(5):466\u201373.","journal-title":"Clin Experiment Ophthalmol"},{"issue":"2","key":"3319_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3319_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243(1):1\u20138.","journal-title":"Ophthalmologica"},{"issue":"1","key":"3319_CR19","doi-asserted-by":"publisher","first-page":"18021","DOI":"10.1038\/s41598-019-54226-7","volume":"9","author":"HE Lode","year":"2019","unstructured":"Lode HE, Gj\u00f8lberg TT, Foss S, Sivertsen MS, Brustugun J, Andersson Y, et al. A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. Sci Rep. 2019;9(1):18021.","journal-title":"Sci Rep"},{"issue":"6","key":"3319_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/eye.2015.28","volume":"29","author":"H Khalili","year":"2015","unstructured":"Khalili H, Sharma G, Froome A, Khaw PT, Brocchini S. Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye. 2015;29(6):820\u20137.","journal-title":"Eye"},{"key":"3319_CR21","unstructured":"EMA. ICH: Q 1 A (R2): stability testing of new drug substances and products\u2014Step 5 2003. Available from: https:\/\/www.ema.europa.eu\/en\/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline."},{"key":"3319_CR22","unstructured":"EMA. International Conference on Harmonization Guideline. Stability testing of new drug substances and products Q5C, 1995. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q5C%20Guideline.pdf."},{"issue":"1","key":"3319_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jps.20727","volume":"96","author":"W Wang","year":"2007","unstructured":"Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96(1):1\u201326.","journal-title":"J Pharm Sci"},{"issue":"51","key":"3319_CR24","doi-asserted-by":"publisher","first-page":"35947","DOI":"10.1039\/D3RA06476J","volume":"13","author":"M Rahban","year":"2023","unstructured":"Rahban M, Ahmad F, Piatyszek MA, Haertl\u00e9 T, Saso L, Saboury AA. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry. RSC Adv. 2023;13(51):35947\u201363.","journal-title":"RSC Adv"},{"key":"3319_CR25","unstructured":"Moore R, Farrell A, Bones J, Cook K, Hempstead U. Optimizing protein aggregate analysis by size exclusion chromatography."},{"key":"3319_CR26","doi-asserted-by":"crossref","unstructured":"Ambrogelly A, Liu Y-H, Li H, Mengisen S, Yao B, Xu W, Cannon-Carlson S, editors. Characterization of antibody variants during process development: the tale of incomplete processing of N-terminal secretion peptide. MAbs; 2012: Taylor & Francis.","DOI":"10.4161\/mabs.21614"},{"key":"3319_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchromb.2018.07.039","volume":"1096","author":"B Bob\u00e1ly","year":"2018","unstructured":"Bob\u00e1ly B, D\u2019Atri V, Lauber M, Beck A, Guillarme D, Fekete S. Characterizing various monoclonal antibodies with milder reversed phase chromatography conditions. J Chromatogr B. 2018;1096:1\u201310.","journal-title":"J Chromatogr B"},{"issue":"1","key":"3319_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.xphs.2019.10.061","volume":"109","author":"M G\u00fchlke","year":"2020","unstructured":"G\u00fchlke M, Hecht J, B\u00f6hrer A, Hawe A, Nikels F, Garidel P, Menzen T. Taking subvisible particle quantitation to the limit: uncertainties and statistical challenges with ophthalmic products for intravitreal injection. J Pharm Sci. 2020;109(1):505\u201314.","journal-title":"J Pharm Sci"},{"issue":"6","key":"3319_CR29","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1089\/jop.2019.0042","volume":"35","author":"M Crul","year":"2019","unstructured":"Crul M, Zandvliet A, Moes JR, Veenbaas T, Smeets O. Bevacizumab for intravitreal injection: impact of sub-visible particles on the shelf-life of repackaged bevacizumab. J Ocul Pharmacol Ther. 2019;35(6):372\u20135.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3319_CR30","unstructured":"WHO. WHO expert committee on biological standardization -Seventy-seventh report. 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03319-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03319-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03319-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:45:16Z","timestamp":1757292316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03319-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3319"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03319-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robert Bj\u00f6rnestedt and Sean Waters are Xbrane Biopharma employees; Au\u0161rin\u0117 Pai\u0161yt\u0117 is an UAB Biotechpharma employee; Fabricio Furlan and Christian Wanner are STADA employees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}